



Penicillin Allergy Delabeling Part II: A Case Based Discussion



Shazia Lutfeali, MD

Allergy & Immunology, Cedars-Sinai Medical
Center


Assistant Professor, Departments of Medicine
and Pediatrics





Penicillin Allergy Delabeling

New 7/2/24 CME Webinar (Free)- Penicillin Allergy Delabeling: An Antibiotic Stewardship Initiative (2024)



Penicillin Allergy Delabeling: An Antibiotic Stewardship Initiative

Webinar on Demand - With Free CME

Penicillin Allergy Delabeling: An Antibiotic Stewardship Initiative

Original release date: June 11, 2024; Termination date: May 16, 2027.

[View the Webinar](#)

Handouts

Download the webinar slides as [full page slides](#) or in [handout](#) format.

Continuing Education Credit(s)

This webinar has been approved for 1 *AMA PRA Category 1 Credit™*.


To request a certificate, you must first [view the webinar](#) and then complete this [form](#).

- Physicians will receive a CME Certificate
- Other learners will receive a Certificate of Attendance. This meets the continuing education requirements of many boards.

<http://publichealth.lacounty.gov/acd/antibioticstewardshipprogram/index.htm>

ph.lacounty.gov/cme/penallergywebinar

Key Points from “Penicillin Allergy Delabeling: An Antibiotic Stewardship Initiative”



LET'S REWIND

- 10-20% of the US population reports a penicillin allergy, but >90% are not allergic
 - True penicillin-associated anaphylaxis is very rare
- Reasons for inaccurate penicillin allergy labels:
 - Mislabeling of adverse effects
 - Initial misdiagnosis (viral exanthem)
 - Waning sensitivity (every year, ~10% of patients lose their penicillin sensitivity)

Case #6



A 43 year old female presents for penicillin allergy delabeling. Her history reveals that she took a course of amoxicillin as a teenager and within several hours of the first dose experienced scattered hives to her torso and extremities. She took a diphenhydramine tablet, took a nap, and the hives resolved by the end of the day.

Question: What is her PEN-FAST score?

- A) 1
- B) 2
- C) 3
- D) 4

PEN	Penicillin allergy reported by patient	☐ If yes, proceed with assessment
F	Five years or less since reaction ^a	☐ 2 points
A	Anaphylaxis or angioedema	☐ 2 points
	OR	
S	Severe cutaneous adverse reaction ^b	
T	Treatment required for reaction ^a	☐ 1 point
		☐ Total points

Case #6 (cont.)

Utilization of PEN-FAST

Answer: 1 (Treatment required)

- Internationally validated clinical decision rule for adult patients
- Score <3 associated with low risk of true penicillin allergy (negative predictive value of 96.3%)
- Also validated in special populations (pregnancy, emergency department, intensive care unit)

PEN	Penicillin allergy reported by patient	☐ If yes, proceed with assessment
F	Five years or less since reaction ^a	☐ 2 points
A	Anaphylaxis or angioedema	☐ 2 points
S	Severe cutaneous adverse reaction ^b	
T	Treatment required for reaction ^a	☐ 1 point
		☐ Total points

Interpretation	
Points	
0	Very low risk of positive penicillin allergy test <1% (<1 in 100 patients reporting penicillin allergy)
1-2	Low risk of positive penicillin allergy test 5% (1 in 20 patients)
3	Moderate risk of positive penicillin allergy test 20% (1 in 5 patients)
4-5	High risk of positive penicillin allergy test 50% (1 in 2 patients)

Case #7



A 33 year old female is questioned about her penicillin allergy history. She states she took amoxicillin several years ago and recalled feeling very nauseous afterwards. She also recalled needing to use her albuterol inhaler for some chest tightness. At the time, her primary care physician switched her to another antibiotic. Looking back, though, she is unsure if the asthma symptoms she experienced were related to amoxicillin ingestion or not. What would be the most appropriate next step in penicillin allergy delabeling?

- A) Graded amoxicillin challenge
- B) Full dose amoxicillin challenge
- C) Penicillin skin testing

Case #7 (cont.)

When to Refer for Penicillin Skin Testing

Answer: Penicillin skin testing

Skin testing recommended for:

- Patients with a history of anaphylaxis
- Reactions occurring < 5 years ago (adult patients)
- Symptoms suggestive of an IgE-mediated reaction (other than benign cutaneous symptoms)

(-) skin test

Oral amoxicillin challenge

(+) skin test

Continued avoidance
and/or Desensitization

Case #8



A 57 year old male undergoes a graded oral amoxicillin challenge in your office. You decide to give him 50mg (1mL of 250mg/5mL solution) and intend to follow this up with a 450mg (9mL of 250mg/5mL solution) dose after a 30 minute monitoring period in between. However, about 15 minutes after taking the 50mg dose, the patient notes itching to his lower lip. A few minutes later, his lip is mildly but visibly swollen. His vital signs are stable and he has no other symptoms.

Question: How should this patient be treated?

- A) Oral antihistamine
- B) Intramuscular epinephrine

Case #8 (cont.)

Management of Acute Reactions

Answer: Oral antihistamine (for presumed allergic angioedema)

- Most reactions consist either of subjective symptoms or minor cutaneous reactions
- Standby medications:
 - Intramuscular and/or intranasal epinephrine
 - Oral antihistamine (2nd generation non-sedating preferred)
 - Inhaled/nebulized bronchodilator
 - H2 blocker
 - Steroids (oral and/or parenteral)

	Drug	Pediatric dosing	Adult dosing
Intramuscular (IM) epinephrine	Epinephrine 1 mg/mL (1: 1000)	<10 kg: 0.1 mg 10-25 kg: 0.15 mg Children >25 kg: use Adult dosing	0.30 mg
Antihistamines	Diphenhydramine	1 to 2 mg/kg/dose (IM or PO); Maximum: 50mg/dose	25-50 mg
	Cetirizine	6m to <2 years: 2.5 mg 2 to 5 years: 2.5-5 mg Children ≥6 years: use Adult dosing	10-20 mg
	Fexofenadine	2 to 11 years: 30-60 mg Children ≥12 years: use Adult dosing	90-360 mg
Glucocorticoids	Prednisone	1-2 mg/kg	20-60 mg
Bronchodilators	Albuterol inhaler	1 inhalation Anaphylaxis: 4-8 inhalations every 20 minutes for 3 doses	2 inhalations Anaphylaxis: 4-8 inhalations every 20 minutes for up to 4 hrs
	Albuterol nebulized	0.15 mg/kg (minimum dose: 2.5 mg) in 3 mL saline, inhaled via nebulizer >12 years old: use Adult dosing	2.5-5 mg every 20 minutes for 3 doses

Case #8 (cont.)

Management of Acute Reactions


Response to challenge	Actions	Results
Subjective symptoms Pruritus without rash Scratchy throat, tongue, or palate Vague gastrointestinal symptoms (eg, nausea)	Obtain vital signs Perform physical exam looking for objective signs to support a minor cutaneous or systemic reaction Increase observation time by 30 min to observe for objective signs of reaction	If no objective signs of reaction, symptoms unlikely an allergic reaction If objective signs of reaction, consider following the "Minor cutaneous reaction" or "Possible systemic (anaphylactic) reaction" pathways below Consider specialty evaluation
Minor cutaneous reaction Flushing Rash Urticaria	Obtain vital signs Ask patient about symptoms, including skin symptoms and other organ systems that are involved in systemic (anaphylactic) reactions Perform physical exam looking for rash type and extent, as well as any other signs suggestive of a systemic (anaphylactic) reaction Treat with antihistamine ^b Nonsedating: cetirizine or fexofenadine Sedating: diphenhydramine Epinephrine for diffuse urticaria ^b Increase observation period by 30 min to observe for signs of systemic reaction or symptom resolution	Patient labeled as penicillin-allergic Consider specialty evaluation
Possible systemic (anaphylactic) reaction Typically involves ≥ 2 organ systems Cutaneous: pruritus, flushing, rash, urticaria, or swelling Respiratory: nasal congestion, runny nose, cough, shortness of breath, chest tightness, wheezing Cardiovascular: faintness, tachycardia, tunnel vision, chest pain, hypotension, sense of impending doom, loss of consciousness Gastrointestinal: nausea, vomiting, cramping, diarrhea Hypotension alone in the setting of a known allergen exposure is also considered anaphylaxis	Assess airway, breathing, circulation Obtain vital signs ^a Place patient in supine position and elevate legs If automated external defibrillator is available, retrieve and bring to bedside Administer intramuscular epinephrine ^b mid-upper outer thigh; repeat every 5-15 min as needed Call 911 Administer oxygen and intravenous fluids, if available Administer adjunctive treatments such as antihistamine, steroids, and bronchodilators ^b	Patient labeled as penicillin-allergic Consider specialty evaluation

Case #8 (cont.)


Management of Acute Reactions

Anaphylaxis is highly likely when any one of the following three criteria is fulfilled


- 1** Sudden onset of an illness (minutes to several hours), with involvement of the skin, mucosal tissue, or both (e.g. generalized hives, itching or flushing, swollen lips-tongue-uvula)



- OR 2** Two or more of the following that occur suddenly after exposure to a *likely allergen or other trigger** for that patient (minutes to several hours)



- OR 3** Reduced blood pressure (BP) after exposure to a *known allergen*** for that patient (minutes to several hours)



NIAID/FAAN Anaphylaxis Criteria

Case #8 (cont.)

Management of Acute Reactions

- Severe reactions are extremely rare
 - Meta-analysis of 56 studies evaluating direct penicillin challenges showed that severe reactions occurred in only 5 of 9225 patients (0.05%)

Case #9



A 19 year old M presents for a scheduled surgical procedure. He is in need of perioperative antibiotics, and cefazolin is the preferred choice. However, he has a history of penicillin allergy listed in his chart.

Question: Can he safely receive cefazolin without any special precautions?


- A) Yes
- B) No

Case #9 (cont.)

Cross-Reactivity Between Penicillin and Cefazolin

Answer: Yes – patient can safely receive cefazolin

- Overall ~2% cross-reactivity between penicillins and cephalosporins
- BUT cefazolin has even lower cross-reactivity with penicillins (due to unique side chain)
 - 0.7% reaction rate to cefazolin among patients with unverified penicillin allergy
 - 0.8% reaction rate to cefazolin among patients with confirmed penicillin allergy



Case #9 (cont.)

Cross-Reactivity Between Penicillin and Cefazolin

Cefazolin Administration
to Patients with History of
Penicillin Hypersensitivity



Recommended Option:
Administer cefazolin
normally

Other Option:
Administer cefazolin via
drug challenge/test dose

“Prospective, Multicenter, Head-to-Head Comparison Between Allergists Versus Nonallergists in Low-Risk Penicillin Allergy Delabeling”

- No difference in delabeling rates between allergist and nonallergist cohorts (93.3% vs. 94.1%)
- Similar improvements reported in health-related quality of life
- Waiting times (referral to penicillin allergy evaluation) significantly shorter for nonallergist vs. allergist cohorts (0.57 vs. 15.7 months)




FIGURE 3. Box-and-whiskers plot of waiting times of allergist vs nonallergist cohorts.

“Delabeling penicillin allergy in a pediatric primary care clinic”

Direct amoxicillin graded challenge and observation performed by a trained pediatric nurse

During observation, patients completed routine healthcare maintenance visit with pediatrician

Outcomes:

- 100% of caregivers reported satisfaction with the challenge
- All delabeled patients reported they would use penicillins when prescribed
- None of the caregivers expressed a preference to have completed testing at an allergist's vs. pediatrician's office

“Oral Amoxicillin Challenges in Low-Risk Children During a Pediatric Emergency Room Visit”

MRN sticker

Penicillin Allergy Questionnaire

1) What age was your child at time of diagnosis? Years Months

2) What symptoms did your child have to the penicillin medication?

LOW risk symptoms		HIGH risk symptoms	
☐	Cough	☐	Blisters (mouth)
☐	Diarrhea	☐	Blood pressure drop
☐	Dizziness	☐	Difficulty breathing
☐	Family history of penicillin allergy	☐	Seizures
☐	Headache	☐	Skin peeling
☐	Itching (isolated / with only low risk)	☐	Syncope
☐	Nausea	☐	Swelling (face)
☐	Runny nose	☐	Swelling (lips)
☐	Vomiting (single episode)	☐	Swelling (throat)
		☐	Wheezing

3) Did any of these symptoms occur within 6 hrs of giving the medication?

Other symptoms	No	Unsure	Yes
☐ Abdominal pain	☐	☐	☐
☐ Itching (with rash)	☐	☐	☐
☐ Rash	☐	☐	☐
☐ Vomiting (multiple episodes)	☐	☐	☐

4) Is this patient low or high risk?

☐ Low

☐ High

(One or more high risk symptoms = high risk)

5) Document low or high risk in Epic

Children 2-16 yrs with history of parent-reported penicillin allergy given a risk-stratifying questionnaire



Randomized to “No Oral Challenge” or “Oral Challenge” (500mg amoxicillin tablet or 520mg liquid)




1 hour observation period

Exclusion criteria:

- Developmental delay
- Contraindication to allergy testing
- Presenting symptoms of rash, vomiting, or asthma
- Admission to hospital (or too acutely ill to participate)

“Oral Amoxicillin Challenges in Low-Risk Children During a Pediatric Emergency Room Visit” (cont.)



Opportunities for Penicillin Allergy Delabeling

- Ambulatory care
- Hospitalized patients
- Preoperative evaluations
- Pediatric patients
- Pregnant patients
- Long-term care facilities
- Oncology patients
- Sexually transmitted infection clinics

Summary

- Inappropriate penicillin allergy labels pose a significant public health concern
- Delabeling can be performed by trained nurses, pharmacists, advanced practice providers, and non-allergist physicians
- Direct amoxicillin challenges are safe and effective for low risk patients

Resources To Aid with Implementation of Delabeling

- Los Angeles County Department of Public Health

Los Angeles County Department of Public Health Antibiotic Stewardship Program

Adult Low-Risk Penicillin Allergy Delabeling Toolkit for Hospitals

- American Academy of Allergy, Asthma, & Immunology

How to Identify Patients at Low Risk of Having a True Penicillin Allergy



How to Conduct an Inpatient Oral Amoxicillin Challenge



Implementing Amoxicillin Challenges in Your Pediatric Office



References

1. Bland CM, Jones BM. Pharmacists Filling the Gap Within Penicillin Allergy Assessment and Skin Testing. *Clin Infect Dis*. 2021 May 18;72(10):1866-1867. doi: 10.1093/cid/ciaa978. PMID: 32663245.
2. Blumenthal KG, Smith LR, Mann JTS, Saliccioli I, Accarino JJO, Shah RJ, Alvi FI, Cardoso-Fernandes A, Ferreira-da-Silva R, Schunemann HJ, Sousa-Pinto B. Reaction Risk to Direct Penicillin Challenges: A Systematic Review and Meta-Analysis. *JAMA Intern Med*. 2024 Nov 1;184(11):1374-1383. doi: 10.1001/jamainternmed.2024.4606. PMID: 39283610; PMCID: PMC11406457.
3. Brillant-Marquis F, Proulx É, Ratnarajah K, Lavoie A, Gauthier A, Gagnon R, Boursiquot JN, Verreault N, Marois L, Bédard MA, Boivin M, Bédard PM, Ouakki M, De Serres G, Drolet JP. Safety of Direct Drug Provocation for the Evaluation of Penicillin Allergy in Low-Risk Adults. *J Allergy Clin Immunol Pract*. 2024 Feb;12(2):451-457.e2. doi: 10.1016/j.jaip.2023.10.035. Epub 2023 Oct 30. PMID: 38572700.
4. Cadot R, Gery P, Lenief V, Nicolas JF, Vocanson M, Tauber M. Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology. *Allergy*. 2025 Jan;80(1):47-62. doi: 10.1111/all.16316. Epub 2024 Sep 18. PMID: 39295209; PMCID: PMC11724259.
5. Castells M, Khan DA, Phillips EJ. Penicillin Allergy. *N Engl J Med*. 2019 Dec 12;381(24):2338-2351. doi: 10.1056/NEJMra1807761. PMID: 31826341
6. Chow TG, McDanel DL, Turner NA, Copaescu AM. Nonallergist Delabeling-Should Penicillin Allergy Delabeling Only Be Performed by Allergists? *J Allergy Clin Immunol Pract*. 2024 Dec 24:S2213-2198(24)01268-6. doi: 10.1016/j.jaip.2024.11.028. Epub ahead of print. PMID: 39725315.
7. Chow TG, Patel G, Mohammed M, Johnson D, Khan DA. Delabeling penicillin allergy in a pediatric primary care clinic. *Ann Allergy Asthma Immunol*. 2023 May;130(5):667-669. doi: 10.1016/j.anai.2023.01.034. Epub 2023 Feb 2. PMID: 36738783.
8. Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA, Bernstein JA, Chu DK, Ellis AK, Golden DBK, Greenhawt MJ, Horner CC, Ledford D, Lieberman JA, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wallace D, Wang J; Chief Editor(s); Khan DA, Golden DBK, Shaker M, Stukus DR; Workgroup Contributors; Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA; Joint Task Force on Practice Parameters Reviewers; Bernstein JA, Chu DK, Ellis AK, Golden DBK, Greenhawt MJ, Horner CC, Ledford D, Lieberman JA, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wallace D, Wang J. Drug allergy: A 2022 practice parameter update. *J Allergy Clin Immunol*. 2022 Dec;150(6):1333-1393.
9. Manivannan V, Decker WW, Stead LG, Li JT, Campbell RL. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. *Int J Emerg Med*. 2009 Apr;2(1):3-5. doi: 10.1007/s12245-009-0093-z. Epub 2009 Feb 25. PMID: 19390910; PMCID: PMC2672985.
10. Lutfeali S, DiLoreto FF, Alvarez KS, Patel SV, Joshi SR, Tarver SA, Khan DA. Maintaining penicillin allergy delabeling: A quality improvement initiative. *J Allergy Clin Immunol Pract*. 2021 May;9(5):2104-2106.e2. doi: 10.1016/j.jaip.2021.01.005. Epub 2021 Jan 20. PMID: 33482418.
11. Samarakoon U, Accarino J, Wurcel AG, Jaggars J, Judd A, Blumenthal KG. Penicillin allergy delabeling: Opportunities for implementation and dissemination. *Ann Allergy Asthma Immunol*. 2023 May;130(5):554-564. doi: 10.1016/j.anai.2022.12.023. Epub 2022 Dec 20. PMID: 36563744

References

12. Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Greenhawt M, Khan DA, Lang DM, Lang ES, Lieberman JA, Portnoy J, Rank MA, Stukus DR, Wang J; Collaborators; Riblet N, Bobrownicki AMP, Bontrager T, Dusin J, Foley J, Frederick B, Fregene E, Hellerstedt S, Hassan F, Hess K, Horner C, Huntington K, Kasireddy P, Keeler D, Kim B, Lieberman P, Lindhorst E, McEnany F, Milbank J, Murphy H, Pando O, Patel AK, Ratliff N, Rhodes R, Robertson K, Scott H, Snell A, Sullivan R, Trivedi V, Wickham A; Chief Editors; Shaker MS, Wallace DV; Workgroup Contributors; Shaker MS, Wallace DV, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Golden DBK, Greenhawt M, Lieberman JA, Rank MA, Stukus DR, Wang J; Joint Task Force on Practice Parameters Reviewers; Shaker MS, Wallace DV, Golden DBK, Bernstein JA, Dinakar C, Ellis A, Greenhawt M, Horner C, Khan DA, Lieberman JA, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wang J. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. *J Allergy Clin Immunol*. 2020 Apr;145(4):1082-1123. doi: 10.1016/j.jaci.2020.01.017. Epub 2020 Jan 28. PMID: 32001253.
13. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin Allergy: A Review. *JAMA*. 2019 Jan 15;321(2):188-199. doi: 10.1001/jama.2018.19283. PMID: 30644987
14. Trubiano JA, Vogrin S, Chua KYL, Bourke J, Yun J, Douglas A, Stone CA, Yu R, Groenendijk L, Holmes NE, Phillips EJ. Development and Validation of a Penicillin Allergy Clinical Decision Rule. *JAMA Intern Med*. 2020 May 1;180(5):745-752. doi: 10.1001/jamainternmed.2020.0403. PMID: 32176248; PMCID: PMC7076536.
15. Vyles D, Antoon JW, Norton A, Stone CA Jr, Trubiano J, Radowicz A, Phillips EJ. Children with reported penicillin allergy: Public health impact and safety of delabeling. *Ann Allergy Asthma Immunol*. 2020 Jun;124(6):558-565. doi: 10.1016/j.anai.2020.03.012. Epub 2020 Mar 26. PMID: 32224207; PMCID: PMC7255916.
16. Vyles D, Chiu A, Routes J, Castells M, Phillips EJ, Visotcky A, Fraser R, Pezzin L, Brousseau DC. Oral amoxicillin challenges in low-risk children during a pediatric emergency department visit. *J Allergy Clin Immunol Pract*. 2020 Mar;8(3):1126-1128.e1. doi: 10.1016/j.jaip.2019.09.022. Epub 2019 Oct 3. PMID: 31586667; PMCID: PMC7332348.
17. Wong JCY, Kan AKC, Chik TSH, Chu MY, Li TCM, Mak HWF, Chiang V, Li PH. Prospective, Multicenter, Head-to-Head Comparison Between Allergists Versus Nonallergists in Low-Risk Penicillin Allergy Delabeling: Effectiveness, Safety, and Quality of Life (HK-DADI2). *J Allergy Clin Immunol Pract*. 2024 Jul;12(7):1801-1808.e2. doi: 10.1016/j.jaip.2024.04.010. Epub 2024 Apr 16. PMID: 38631522.